Volume 6.31 | Aug 21

Prostate Cell News 6.31 August 21, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
 
TOP STORY
Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Non-Coding RNA in Prostate Cancer
Scientists characterized the transcriptomic differences between untreated prostate cancer (PC) and locally recurrent castration-resistant PC (CRPC). They reported the identification of 145 previously unannotated intergenic long non-coding RNA transcripts or isoforms that are associated with PC or CRPC. [Cancer Res] Abstract
ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Cabozantinib Inhibits Abiraterone’s Upregulation of IGF-1R Phosphorylation and Enhances Its Anti-Prostate Cancer Activity
Three prostate cancer cell lines were used to interrogate the in vitro molecular and anti-proliferative effects of the single agents and combination of cabozantinib and abiraterone. The in vivo impact of the combination was assessed using the LAPC4-CR xenograft mouse model. [Clin Cancer Res] Abstract

Regulation of c-Myc Expression by the Histone Demethylase JMJD1A Is Essential for Prostate Cancer Cell Growth and Survival
The authors found that JMJD1A knockdown in prostate cancer cells antagonizes their proliferation and survival. JMJD1A regulated c-Myc stability, likely by inhibiting HUWE1, an E3 ubiquitin ligase known to target degradation of several substrates including c-Myc. [Oncogene] Abstract

The Prognostic Significance of CXCL16 and Its Receptor C-X-C Chemokine Receptor 6 in Prostate Cancer
Investigators examined how the expression of CXCR16/C-X-C chemokine receptor 6 in prostate cancer was related to clinicopathological features and activation of inflammatory cells. [Am J Pathol] Full Article

Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression
Scientists demonstrated that ABC294640 abrogates signaling pathways requisite for prostate cancer (PCa) growth and proliferation. Key findings validate that ABC294640 treatment of early stage and advanced PCa models downregulate Myc and AR expression and activity. [Mol Cancer Res] Abstract

In Vivo Studies of the PARP Inhibitor, AZD-2281, in Combination with Fractionated Radiotherapy: An Exploration of the Therapeutic Ratio
Investigators tested the PARP inhibitor AZD-2281 as a radiosensitizing agent under oxic and hypoxic conditions for clonogenic survival in vitro and in vivo using the human prostate cancer cell line, 22Rv1. [Radiother Oncol] Abstract

Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate
Researchers report that BE prostate cells have a higher competence to utilize fatty acids as energy source than prostate cancer cells as shown not only by increased cell viability upon fatty acid supplementation but also by an increased ß-oxidation of fatty acids, although the base-line respiration was 2-fold higher in prostate cancer cells. [PLoS One] Full Article

CLINICAL RESEARCH

Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR-2 as Targets for Growth Inhibition of Prostate Cancer
Investigators performed parallel investigations in cabozantinib-treated patients in a Phase II trial and simultaneously in patient-derived xenograft models to better understand the roles of MET and VEGFR-2 as targets for prostate cancer therapy. [Clin Cancer Res] Abstract

Dysfunction of PSA-Specific CD8+ T Cells in Prostate Cancer Patients Correlates with CD38 and Tim-3 Expression
Researchers assessed the preexisting cellular immunity against prostate-specific antigen in untreated prostate cancer patients and healthy controls through measurement of the phenotype and function of CD8+ T cells. [Cancer Immunol Immunother] Abstract

Weekend-Free Culture hPSCs with mTeSR™1 or TeSR™-E8™
 
REVIEWS
Androgen Receptor and Prostate Cancer Stem Cells: Biological Mechanisms and Clinical Implications
The authors discuss prostate cancer stem cells (PCSCs) and heterogeneity of androgen receptor (AR) expression in primary, metastatic and treatment-failed prostate cancer (PCa). They illustrate the potential mechanisms whereby AR+ and AR- PCSCs may employ to propagate PCa at the population level, mediate therapy resistance, and metastasize. [Endocr Relat Cancer] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Madison Vaccines Announces Patient Dosing Underway in Clinical Trial Pairing Its Lead Prostate Cancer Vaccine, Mvi-816, with Pd1 Inhibitor Pembrolizumab
Madison Vaccines Incorporated announced dosing has begun in a combination trial for MVI-816 (pTVG-HP), its lead prostate cancer vaccine, paired with pembrolizumab (Keytruda®), a PD-1 inhibitor, also called a checkpoint inhibitor. [Madison Vaccines Incorporated] Press Release

$120,000 in Cancer Research Pilot Grants Awarded to Promote Collaboration
The University of Cincinnati Cancer Institute has awarded four $40,000 research pilot grants to aid in the interaction and collaboration between basic scientific and clinical investigators and facilitate the translation of laboratory findings into clinical therapies. [University of Cincinnati] Press Release

$52 Million NIH Grant Advances Clinical and Translational Research at UC San Diego
The Clinical and Translational Research Institute at University of California, San Diego has received a five-year Clinical and Translational Science Award for approximately $52 million from the National Center for Advancing Translational Science, part of the National Institutes of Health (NIH). [UC San Diego Health] Press Release

From our sponsor:
Want to learn more about ALDH in breast cancer treatment response?
Listen to the podcast.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW The Presence and Future of the RAS Pathway: From Function and Genomics to Inhibition
October 5-7, 2015
Pamplona, Spain

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Computational Biologist – Prostate Cancer (Cancer Research UK Manchester Institute)

NEW Bioinformatician (GenomeDx Biosciences)

Staff Scientist – Cancer Modeling (Fred Hutchinson Cancer Research Center)

Postdoctoral Associate – Cancer Biology (Cornell University)

Research Associate – Prostate Cancer (Imperial College London)

Harry Eagle Scholar Awards for Postdoctoral Candidates (Albert Einstein College of Medicine of Yeshiva University)

Postdoctoral Positions – Cancer Research (Rutgers University)

Postdoctoral Position – Functional Cancer Genomics (Institute of Oncology Research)

Assistant Professor- Urology (University of California, Los Angeles)

Postdoctoral Fellows – Molecular Mechanisms of Prostate Cancer Progression and Therapeutic Resistance (Tulane University School of Medicine)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us